VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
hMSC
Phase 2
Biologic
S
Stemedica Cell Technologies, Inc.
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Mesenchymal Stem Cells
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Mesenchymal Stem Cells
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Mesenchymal Stem Cells
1 trial
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
Recruiting
·
B
Bernard (Barry) Baumel
·
Phase 2
·
NCT06781333
·
8 enrolled
COVID-19
1 trial
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
Unknown status
·
S
Stemedica Cell Technologies, Inc.
·
Phase 2
·
NCT04780685
·
40 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for hMSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
hMSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for hMSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Stemedica Cell Technologies, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 2
[1]
Company
S
Stemedica Cell Technologies, Inc.
Related News